CLINICAL_TRIALS
trial_result
· 2021-01-22
Clinical Trial Update: TBE Seropersistence up to 10 Years After First Booster in Adults [Phase 4]
Summary
Phase 4 trial update reporting seropersistence of Tick-borne Encephalitis antibodies up to 10 years after first booster in adults.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Tick-borne Encephalitis (TBE) | Phase 4 | Status: COMPLETED